In this Issue:
Long-term data from the Gothenburg Trial of Mammographic Screening
Anastrozole ± pictilisib in ER+ disease
Adding pictilisib to fulvestrant: no clinical benefit
21-Gene Recurrence Score assay influences use of chemotherapy
Patient-reported outcomes from the SOFT study
Ovarian function suppression: no cognitive dysfunction
NeoSphere 5-year PFS, DFS data on adjuvant pertuzumab
No benefit with neoadjuvant bevacizumab
Sequential vs concurrent adjuvant treatment in HER2 nonamplified disease
Long-term health consequences of ovarian ablation
Please login below to download this issue (PDF)